331 related articles for article (PubMed ID: 15681915)
1. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Talwalkar JA; Angulo P; Keach JC; Petz JL; Jorgensen RA; Lindor KD
J Clin Gastroenterol; 2005 Feb; 39(2):168-71. PubMed ID: 15681915
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis.
Jones EA; ten Kate FJ; ter Borg F; Houben M; Reesink HW; Chamuleau RA
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1165-9. PubMed ID: 10524648
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
[TBL] [Abstract][Full Text] [Related]
4. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
5. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
6. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Treiber G; Malfertheiner P
J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
[No Abstract] [Full Text] [Related]
8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
9. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for primary biliary cirrhosis--convergent thinking.
Altschuler EL
Eur J Gastroenterol Hepatol; 2000 May; 12(5):587. PubMed ID: 10833107
[No Abstract] [Full Text] [Related]
13. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
15. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
Nikolovska D; Vasilev P; Mikhova A
Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
[TBL] [Abstract][Full Text] [Related]
17. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
18. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
Angulo P; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
20. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
